Rani Therapeutics director buys 36,000 shares

Imran Mir A, a director and 10% owner of Rani Therapeutics Holdings, Inc., purchased 36,000 shares of Class A Common Stock on July 21, 2026 at a weighted average price of about $0.69 per share, in multiple transactions between $0.688 and $0.69.

Rhea-AI Filing Summary

Imran Mir A, a director and 10% owner of Rani Therapeutics Holdings, Inc., purchased 36,000 shares of Class A Common Stock on July 21, 2026 at a weighted average price of about $0.69 per share, in multiple transactions between $0.688 and $0.69. After this purchase, he directly holds 2,119,334 Class A shares and has indirect interests in 74,139 Class A and 22,660,053 Class B shares through affiliated entities, for which he disclaims beneficial ownership beyond his pecuniary interest.

Insider Trade Summary

Net Buyer: 36,000 shares

Net Buy 3 txns

Insider IMRAN MIR A

Role Director, 10% Owner

Bought 36,000 shs ($25K)

Type	Security	Shares	Price	Value
Purchase	Class A Common Stock F1	36,000	$0.69	$25K
holding	Class A Common Stock F2	--	--	--
holding	Class B Common Stock F3	--	--	--

Holdings After Transaction: Class A Common Stock — 2,119,334 shares (Direct); Class A Common Stock — 74,139 shares (Indirect, See footnote); Class B Common Stock — 22,660,053 shares (Indirect, See footnote)

Footnotes (3)

1. F1. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.688 to $0.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
2. F2. The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. InCube Labs, L.L.C. is wholly-owned by the Reporting Person and his family. Represents 52,781 shares of Class A Common Stock of the Issuer held by InCube Ventures II, L.P., 13,664 shares of Class A Common Stock of the Issuer held by InCube Labs, L.L.C., and 7,694 Class A Shares held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
3. F3. The Reporting Person is a General Partner of InCube Ventures II, L.P., and InCube Labs, LLC is wholly-owned by the Reporting Person and his family. Represents 22,411,124 Class B Shares held by InCube Labs, LLC and 248,929 Class B Shares held by InCube Ventures II, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Key Figures

Shares purchased: 36,000 shares of Class A Common Stock Weighted average purchase price: $0.69 per share Direct Class A holdings after transaction: 2,119,334 shares +3 more

6 metrics

Shares purchased 36,000 shares of Class A Common Stock Non-derivative purchase on July 21, 2026

Weighted average purchase price $0.69 per share Class A purchase, trades between $0.688 and $0.69

Direct Class A holdings after transaction 2,119,334 shares Total Class A Common Stock directly held following purchase

Indirect Class A holdings 74,139 shares Class A Common Stock held via InCube Ventures II, L.P., InCube Labs, L.L.C., and Rani Investment Corp.

Indirect Class B holdings 22,660,053 shares Class B Common Stock held via InCube Labs, LLC and InCube Ventures II, L.P.

Net share direction 36,000 net buy shares transactionSummary reports net-buy direction for this filing

Key Terms

weighted average price, beneficial ownership, pecuniary interest, General Partner

4 terms

weighted average price financial

"The price reported is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

beneficial ownership financial

"The Reporting Person disclaims beneficial ownership of these securities..."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"except to the extent of his pecuniary interest therein."

General Partner financial

"The Reporting Person is a General Partner of InCube Ventures II, L.P."

A general partner is the person or firm that runs an investment partnership and legally represents it — they make the day-to-day decisions, choose which assets to buy or sell, and are responsible for the partnership’s obligations. Investors care because the general partner’s judgment, risk-taking and fee and profit-sharing arrangements determine both the potential returns and the level of exposure to losses; think of the GP as the ship’s captain whose skill and honesty shape the voyage’s outcome.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did insider Imran Mir A report in the latest RANI Form 4?

Imran Mir A reported buying 36,000 Rani Therapeutics Class A shares on July 21, 2026 at a weighted average price of about $0.69 per share, increasing his directly held Class A position to 2,119,334 shares and updating his indirect holdings.

At what prices did Imran Mir A buy RANI Class A shares?

He purchased 36,000 Class A shares in multiple trades at prices ranging from $0.688 to $0.69 per share, with a reported weighted average price of approximately $0.69 per share, as detailed in the footnote to the transaction.

How many RANI shares does Imran Mir A hold after this transaction?

After the transaction, he directly holds 2,119,334 Class A shares. He also has indirect interests in 74,139 Class A and 22,660,053 Class B shares through entities he is associated with, while disclaiming beneficial ownership beyond his pecuniary interest.

How are Imran Mir A’s indirect RANI holdings structured?

Indirect Class A holdings of 74,139 shares are held via InCube Ventures II, L.P., InCube Labs, L.L.C., and Rani Investment Corp. Indirect Class B holdings of 22,660,053 shares are held mainly by InCube Labs, LLC and InCube Ventures II, L.P., subject to pecuniary-interest disclaimers.

Was Imran Mir A’s RANI share purchase under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox was not marked, so the reported 36,000-share purchase is not identified as being made under a Rule 10b5-1 trading plan, and no footnote describes it as a pre-arranged plan trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/23/2026 - 04:10 PM Accepted by SEC EDGAR 07/23/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

IMRAN MIR A

(Last) (First) (Middle)

C/O RANI THERAPEUTICS LLC

2051 RINGWOOD AVE.

(Street)

SAN JOSE CALIFORNIA 95131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rani Therapeutics Holdings, Inc. [ RANI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	07/21/2026		P		36,000	A	$0.69(1)	2,119,334	D
Class A Common Stock								74,139	I	See footnote(2)
Class B Common Stock								22,660,053	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.688 to $0.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2. The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. InCube Labs, L.L.C. is wholly-owned by the Reporting Person and his family. Represents 52,781 shares of Class A Common Stock of the Issuer held by InCube Ventures II, L.P., 13,664 shares of Class A Common Stock of the Issuer held by InCube Labs, L.L.C., and 7,694 Class A Shares held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

3. The Reporting Person is a General Partner of InCube Ventures II, L.P., and InCube Labs, LLC is wholly-owned by the Reporting Person and his family. Represents 22,411,124 Class B Shares held by InCube Labs, LLC and 248,929 Class B Shares held by InCube Ventures II, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

	/s/ Mir A Imran	07/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)